Abstract
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
Highlights
Ovarian cancer (OVC) ranks as the fifth most common cancer in women and has the highest mortality rate among gynecologic malignancies [1,2]
Pre-screening of potential OVC biomarkers using bioinformatics tools and an OVC cell line library To pre-screen human genes that have a high potential for use as early detection biomarkers, the BioXM bioinformatics platform was used with query strings including ovarian, biomarker, up-regulation, down-regulation and over-expression
Given the high mortality rate of OVC in later stages [77], and the lack of reliable biomarkers for detection of early stage OVC, this study focused on determining whether kallikrein-related peptidase 6 (KLK6) and kallikrein-related peptidase 7 (KLK7) can be used as potential early detection biomarkers
Summary
Ovarian cancer (OVC) ranks as the fifth most common cancer in women and has the highest mortality rate among gynecologic malignancies [1,2]. CA-125 serum expression is elevated above normal levels in early stage (23%) and late stage (80%) disease, this antigen lacks specificity and sensitivity for use as a single marker for early OVC detection [6,7]. After the approval of the OVA1 test, the FDA approved the use of the Risk of Ovarian Malignancy Algorithm (ROMA) that involves CA-125 and HE4 measurements and a definition of menopausal status [14]. These tests suggest that use of a combination of multiple markers can generate synergistic advantages over single marker diagnostics [15]. This study was conducted to identify relevant biomarkers for both laparoscopic and serum diagnostics in ovarian cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
